Veterinary Medicine Information website

RESFLOR 300/16.5 MG/ML SOLUTION FOR INJECTION FOR CATTLE

Authorised
  • Florfenicol
  • Flunixin meglumine

Product identification

Medicine name:
RESFLOR 300/16.5 MG/ML SOLUTION FOR INJECTION FOR CATTLE
Active substance:
  • Florfenicol
  • Flunixin meglumine
Target species:
  • Cattle
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Florfenicol
    300.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Flunixin meglumine
    27.40
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cattle
      • Meat and offal
        46
        day
      • Milk
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01BA99
Authorisation status:
  • Valid
Authorised in:
  • Germany
Available in:
  • Germany
Package description:
  • Carton box containing 250 mL vial
  • Carton box containing 100 mL vial

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Vet Pharma Friesoythe GmbH
Responsible authority:
  • Federal Office Of Consumer Protection And Food Safety
Authorisation number:
  • 401025.00.00
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0167/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 19/12/2024